Author Interviews, Gastrointestinal Disease, Mental Health Research / 08.02.2023

MedicalResearch.com Interview with: [caption id="attachment_59989" align="alignleft" width="144"]Yuan, Zhongshang Dr. Zhongshang Yuan[/caption] Yuan, Zhongshang PhD Department of Biostatistics School of Public Health Shandong University Jinan, Shandong, China What is the background for this study? Response: Comorbidities and genetic correlations between gastrointestinal tract diseases and psychiatric disorders have been widely reported, with the gut-brain axis (GBA) hypothesized as a potential biological basis. However, it is unclear the degree to which the shared genetic determinants contribute to these associations underlying GBA.
Author Interviews, Cancer Research, Gastrointestinal Disease / 20.05.2022

MedicalResearch.com Interview with: [caption id="attachment_59182" align="alignleft" width="150"]Bashar J. Qumseya, MD, MPH, FASGE Associate Professor of Medicine Chief of Endoscopy University of Florida, Gainesville  Dr. Qumseya[/caption] Bashar J. Qumseya, MD, MPH, FASGE Associate Professor of Medicine Chief of Endoscopy University of Florida, Gainesville  MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Barrett’s esophagus (BE), is a premalignant condition that can lead to esophageal cancer (called esophageal adenocarcinoma). Both diseases have historically been thought of as diseases of elderly white males. While both diseases have been on the rise in the elderly population, we noted that some cancers are becoming more common at younger ages. We wanted to see if the prevalence of BE and EC are increasing at younger ages.  We aimed to assess the prevalence of BE in and EAC based on age group in a large database of over 5 million patients. 
Author Interviews, Gastrointestinal Disease, Transplantation / 19.05.2022

MedicalResearch.com Interview with: [caption id="attachment_59172" align="alignleft" width="150"]Karn Wijarnpreecha, MD, MPH Lead researcher of the study Transplant Hepatology Fellow University of Michigan Dr. Wijarnpreecha[/caption] Karn Wijarnpreecha, MD, MPH Lead researcher of the study Transplant Hepatology Fellow University of Michigan MedicalResearch.com:  What is the background for this study?  Response: Nonalcoholic fatty liver disease (NAFLD) can develop in persons who are not overweight or obese (“lean person with NAFLD”) and approximately 10-20% of NAFLD were lean. NAFLD is a multisystem diseases that associated with cardiovascular diseases, metabolic diseases (diabetes, hypertension, and dyslipidemia), or chronic kidney disease. Whether lean persons with NAFLD have lower prevalence of cirrhosis, CVD, CKD than non-lean persons with NAFLD remains inconclusive.
Author Interviews, Biomarkers, BMJ, Gastrointestinal Disease, Pancreatic / 09.03.2022

MedicalResearch.com Interview with: [caption id="attachment_58857" align="alignleft" width="125"]Ece Kartal, PhD Postdoctoral Fellow Saez-Rodriguez Group Universitätsklinikum Heidelberg Institute for Computational Biomedicine Heidelberg Dr. Kartal[/caption] Ece Kartal, PhD Postdoctoral Fellow Saez-Rodriguez Group Universitätsklinikum Heidelberg Institute for Computational Biomedicine Heidelberg MedicalResearch.com:  What is the background for this study?    Response: Pancreatic cancer is one of the deadliest types of cancer: although incidence rates are relatively low (only few people develop pancreatic cancer in their lifetimes), it has a high lethality, with a five year survival rate of less than ~5%. Pancreatic cancer symptoms are generally unspecific so that the disease is usually detected very late which further  limits therapeutic options. In light of this, earlier detection of pancreatic cancer could dramatically improve prognosis, but there are currently no affordable and non-invasive tests available in the clinic. For pancreatic ductal adenocarcinoma (PDAC),the most common form of pancreatic cancer, it was previously found that the oral, gut and pancreatic microbiome are risk factors and may affect prognosis .
Author Interviews, Duke, Gastrointestinal Disease, Nature, Sugar / 17.01.2022

MedicalResearch.com Interview with: Laura Rupprecht, PhD Postdoctoral Fellow Kelly L Buchanan The Laboratory of Gut Brain Neurobiology Duke Medicine – GI Diego V. Bohórquez PhD Associate Professor in Medicine Duke Institute for Brain Sciences Durham, NC MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: In 2018, my laboratory discovered that a cell type in the gut epithelium synapses with the vagus nerve, the nerve which connects the gut and the brain. These gut cells are called neuropod cells. Neuropod cells transduce sugar within milliseconds using the neurotransmitter glutamate. Since then, we have been interested in defining how this rapid communication between neuropod cells and the brain regulates behavior. – Diego Bohórquez Over a decade ago, it was shown that the gut is the key site for discerning sugar and non-caloric sweetener. But the specific cell in the gut that underlies this effect was unknown. – Kelly Buchanan  
Author Interviews, Environmental Risks, Gastrointestinal Disease / 11.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58634" align="alignleft" width="150"]Morgan Walker Ph.D. Candidate, UNC-Chapel Hill Chemistry Redinbo Laboratory Morgan Walker[/caption] Morgan Walker Ph.D. Candidate, UNC-Chapel Hill Chemistry Redinbo Laboratory MedicalResearch.com: What is the background for this study? Where is triclosan commonly found? Response: Triclosan is a commonly found antibacterial compound present in hand soaps, toothpastes, athletic clothes, and children’s toys. A previous study by the Zhang group (corresponding author on this publication) found that antimicrobial compounds including triclosan increased inflammation (similar to that of inflammatory bowel disease (IBD)) and tumor formation in the colon. These effects were observed only in mice with an intact gut microbiome, not in germ-free mice which lack a gut microbiome, suggesting that the gut microbiome is somehow responsible for the toxicity of triclosan to the gut. Our study investigates how gut bacteria promote triclosan toxicity in the gut 
Author Interviews, Cancer Research, Gastrointestinal Disease, Science / 13.08.2021

MedicalResearch.com Interview with: Dr Lizhe Zhuang PhD Dr Karol Nowicki-Osuch PhD Dr. Rebecca C. Fitzgerald MD Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge UK [caption id="attachment_43740" align="alignleft" width="200"]Barrett's Esophagus -wikipedia Barrett's Esophagus -Wikipedia[/caption] MedicalResearch.com: What is the background for this study? Barrett’s oesophagus affects about one out of 100 people in the UK and is thought to be a precancerous lesion of a more deadline cancer, oesophageal adenocarcinoma. Barrett’s is a condition where the squamous cells in the lower part of oesophagus are replaced by a special type of columnar cells, which look like intestine, a far distant organ, raising a question where are these columnar cells come from. Many theories have been proposed in the past decades and no agreement was reached, and many conclusions were based on mouse models which do not recap the human condition. We therefore collected fresh samples of human tissues that correspond to all the possible theories and assessed them all together using state of the art technologies. 
Author Interviews, Beth Israel Deaconess, Gastrointestinal Disease, NEJM / 01.07.2021

MedicalResearch.com Interview with: [caption id="attachment_57710" align="alignleft" width="152"]Prof. Schuppan, MD, PhD Prof. Schuppan, MD, PhD[/caption] Prof. Dr. D. Schuppan, MD, PhD Professor of Medicine Director Institute of Translational Immunology University Medical Center of the Johannes Gutenberg University Consultant Gastroenterologist and Hepatologist Director Celiac and Small Intestinal Disease Center Director Center for Food Intolerances and Autoimmunity Director Liver Fibrosis and Metabolism Research Research Center for Immune Therapy (FZI) Mainz Project for Chemical Allergology (MPCA) Mainz, Germany Professor of Medicine, Division of Gastroenterology Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA 02215 MedicalResearch.com: What is the background for this study? Response: Celiac disease (CeD) is a common intestinal inflammatory disease that affects about 1% of most wheat consuming populations worldwide. CeD is caused by the ingestion of gluten containing foods, such as wheat, spelt, rye and barley, that activate small intestinal inflammatory T cells. The only current therapy is the rigorous avoidance of even traces of gluten in the daily diet, which is difficult and a social and psychological burden. We previously identified the body’s own enzyme tissue transglutaminase (TG2) as the CeD autoantigen. Moreover, TG2 drives celiac disease pathogenesis by enzymatically modifying dietary gluten peptides that makes them more immunogenic. We therefore developed an oral small molecule (ZED1227) that specifically inhibits TG2 activity in the intestine. While this should attenuate CeD in patients exposed to dietary gluten, it was unclear if  it could prevent gluten induced intestinal inflammation and damage.
Author Interviews, Gastrointestinal Disease, Opiods / 24.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57478" align="alignleft" width="200"]Frank Peacock, MD, FACEP, FACC Professor of Emergency Medicine, Associate Chair Research Director, Department of Emergency Medicine Baylor College of Medicine Houston, Texas Dr. Peacock[/caption] Frank Peacock, MD, FACEP, FACC Professor of Emergency Medicine, Associate Chair Research Director, Department of Emergency Medicine Baylor College of Medicine Houston, Texas MedicalResearch.com: What is the background for this study?  Response: Emergency medicine (EM) physicians, like myself, are always looking for ways to improve the patient experience. Often times, we will encounter a patient in the emergency department (ED) who is presenting with one of the most common side effects of opioids, which is opioid-induced constipation (OIC). OIC impacts 40-80% of patients on long-term opioid therapy[i],[ii] and may lead to emergency room visits which are associated with a significant burden on patients and the healthcare system. We wanted to compare the impact of treating OIC patients with FDA-approved prescription medications for OIC versus the impact of not treating OIC patients with an FDA-approved prescription medication for OIC in the ED setting to better understand the impact to overall ED costs and the length of stay for a hospitalized patient.
Author Interviews, Gastrointestinal Disease / 24.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57458" align="alignleft" width="200"]Nicholas J. Talley, MD, PhD Pro Vice-Chancellor, Global ResearchUniversity of Newcastle, Australia Adjunct Professor of Medicine Division of Gastroenterology and Hepatology; Department of Medicine University of North Carolina at Chapel Hill Dr. Talley[/caption] Nicholas J. Talley, MD, PhD Pro Vice-Chancellor, Global ResearchUniversity of Newcastle, Australia Adjunct Professor of Medicine Division of Gastroenterology and Hepatology; Department of Medicine University of North Carolina at Chapel Hill    MedicalResearch.com: What is the background for this study? What is meant by Eosinophilic Gastritis and/or Duodenitis?  Response: Eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) is an eosinophilic gastrointestinal disease (EGID) characterized by chronic gastrointestinal (GI) symptoms and elevated eosinophils in the stomach and/or the duodenum (the first part of the small intestine). When patients have both EG and EoD, it is sometimes referred to as eosinophilic gastroenteritis (EGE). You may have heard of eosinophilic esophagitis (EoE), which is the more well understood EGID characterized by elevated eosinophils in the esophagus. Until recently, EG/EoD was thought to be very rare, but prevalence had never been assessed in a prospective, systematic manner. New research indicates that EG/EoD may be a common cause of chronic, moderate-to-severe GI symptoms. Related, millions of patients in the United States suffer with chronic GI symptoms or are diagnosed with a functional GI disorder (FGID). FGIDs are diagnoses of exclusion, and excitingly the study results we present at DDW 2021 suggest that EG/EoD may be the underlying cause of many of these patients’ chronic, moderate-to-severe GI symptoms.
Author Interviews, Gastrointestinal Disease, Race/Ethnic Diversity / 23.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57461" align="alignleft" width="142"]Edward L. Barnes, MD, MPH Assistant Professor of Medicine Division of Gastroenterology and Hepatology Dr. Barnes[/caption] Edward L. Barnes, MD, MPH Assistant Professor of Medicine Division of Gastroenterology and Hepatology UNCHealth Care and a medical advisor to the Global Healthy Living Foundation MedicalResearch.com: What is the background for this study? Response: Although historically inflammatory bowel diseases (IBDs) have been considered diseases of non-Hispanic whites, the current burden of Crohn’s disease (CD) and ulcerative colitis (UC) in minority populations is largely unknown. I n our study, we evaluated the relative prevalence of CD and UC across racial and ethnic groups within the National Patient-Centered Clinical Research Network (PCORnet) and compared the racial/ethnic distribution of IBD in PCORnet to that of the United States (US) census data, the overall PCORnet population, and PCORnet patients with selected immune-mediated conditions.
Author Interviews, Diabetes, Gastrointestinal Disease, Weight Research / 16.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57425" align="alignleft" width="200"]Dr. Hoff Dr. Hoff[/caption] Anna Carolina Hoff, MD Lead researcher on the study Founder and Clinical Director Angioskope Brazil São José dos Campos  MedicalResearch.com: What is the background for this study? Response: Obesity is a chronic disease that has become a global pandemic, and its prevalence continues to increase. Overweight (Body Mass Index (BMI) ≥ 27 kg/m2) and obesity (BMI ≥ 30kg/m2) lead to numerous clinical comorbidities, including metabolic, cardiovascular, oncologic, and mental health disorders. It is challenging to achieve significant and sustained weight loss with diet and lifestyle modification alone. Additionally, a reversal of obesity-related co-morbidities and improvement in quality of life entails a percent total body weight loss (%TBWL) of between 5-10%, which is rarely achieved with medications alone. The Endoscopic Sleeve Gastroplasty (ESG) results in a %TBWL between 14.6%-19.7% at 18-24 months,  and improvements in systolic blood pressure (SBP), HbA1c, and dyslipidemia at 12 months.
Author Interviews, Gastrointestinal Disease, Imperial College, Probiotics, Pulmonary Disease, Weight Research / 16.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57422" align="alignleft" width="187"]Benjamin Mullish PhD NIHR Academic Clinical Lecturer Department of Metabolism Digestion and Reproduction Imperial College Dr. Mullish[/caption] Benjamin Mullish PhD NIHR Academic Clinical Lecturer Department of Metabolism Digestion and Reproduction Imperial College MedicalResearch.com: What is the background for this study? Which probiotic did you use and why?  Response: We recently reported the results of a randomized, double-blind placebo-controlled trial in which participants who were overweight or with obesity (aged between 30-65 years of age) were randomized to receive probiotics or placebo for six months.  The primary focus was on weight loss and metabolism.  The probiotic used was Lab4P, containing three different strains of Bifidobacteria and two of Lactobacilli, which have shown to be safe and efficacious for use in rodent models and earlier clinical studies. Of note, probiotics have also been shown to have other beneficial effects upon human health.  Previous studies have suggested that they may have a role in preventing upper respiratory tract infections (URTIs) in healthy people and children; however, this has not been explored in older people or overweight/ people with obesity, even though such groups have higher rates of URTIs. We looked back at our trial, and reviewed symptom diaries completed by participants daily during the study.  We were looking at recorded symptoms most consistent with upper respiratory tract symptoms (including cough, wheezing and headache), and explored if rates of these were different between those participants taking probiotics compared to placebo over the six month course of the study.  
Author Interviews, Brigham & Women's - Harvard, Colon Cancer, Gastrointestinal Disease, Sugar / 06.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57364" align="alignleft" width="150"]Dr. Jinhee Hur Dr. Jinhee Hur[/caption] Jinhee Hur, PhD Research Fellow Department of Nutrition Harvard T.H. Chan School of Public Health Boston, MA 02115 MedicalResearch.com: What is the background for this study? Response: Early-onset colorectal cancer (EO-CRC, age <50 years at diagnosis) is rapidly rising in the US since the mid-1980s, with an unclear understanding of its etiology and contributors to the rise. Sugar-sweetened beverages (SSBs) exert adverse metabolic repercussions throughout the life course, including insulin resistance and inflammation. Higher SSB intake can induce obesity, which has been linked to risk of EO-CRC. A recent experimental study also suggests that high fructose corn syrup, a primary sweetener in SSBs, may promote colon tumor growth, independent of metabolic dysregulation. In the US, SSB consumption has dramatically increased during the 2nd half of the 20th century, and adolescents and young adults have been the heaviest SSB drinkers across all age groups. Thus, we expect SSBs may be an emerging risk factor for EO-CRC and likely contribute to the rising incidence of EO-CRC.
Author Interviews, Cancer Research, Gastrointestinal Disease, Genetic Research / 03.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57297" align="alignleft" width="114"]Judy H. Cho, MD, Dean of Translational Genetics Director of The Charles Bronfman Institute for Personalized Medicine Icahn School of Medicine at Mount Sinai Dr. Cho[/caption] Judy H. Cho, MD, Dean of Translational Genetics Director of The Charles Bronfman Institute for Personalized Medicine Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Would you briefly describe Crohn's disease? Whom does it primarily affect? Response: Crohn’s disease is a chronic inflammatory intestinal disease, which affects ~3 million Americans a year. Its most typical age of onset ranges from 15-30 years, and many of those diagnosed also exhibit frequent abnormal healing and complications that constrict the digestive tract. The highest risk genetic mutations that increase risk for Crohn’s disease are found in the gene NOD2; these were first reported 20 years ago. Biological mechanisms by which NOD2 mutations drive Crohn’s disease, and especially fibrotic complications, have been incompletely described up until this point. Further, the reasons why many patients fail to respond to the commonly administered anti-TNF treatments also remain incompletely understood.
Author Interviews, COVID -19 Coronavirus, Gastrointestinal Disease / 01.11.2020

MedicalResearch.com Interview with: [caption id="attachment_55810" align="alignleft" width="190"]Darbaz Adna​n, MBChB Lab Research Assistant Department of Internal Medicine - Section of Gastroenterology Rush University Medical Center Chicago, Illinois 60612 Dr. Adnan[/caption] Darbaz Adna​n, MBChB Lab Research Assistant Department of Internal Medicine - Section of Gastroenterology Rush University Medical Center Chicago, Illinois 60612 MedicalResearch.com: What is the background for this study? Response: - We have conducted a large study of over 1000 patients at a major COVID-19 response center in Chicago at Rush University Medical Center, to assess for the frequency of initial GI symptoms (diarrhea, vomiting, abdominal pain) and evaluate whether these symptoms in adult COVID-19 positive could predict the disease course. Overall, 22.4% of our patients reported at least one GI symptom at the onset of their infection, with nausea/vomiting being the most common complaint. GI symptoms in COVID-19 patients were associated with worse outcomes.
Annals Internal Medicine, Author Interviews, Esophageal, Gastrointestinal Disease / 20.10.2020

MedicalResearch.com Interview with: 加藤元嗣　Mototsugu KATO MD PhD 院長  独立行政法人国立病院機構函館病院 Director, National Hospital Organization Hakodate National Hospita MedicalResearch.com: What is the background for this study? Response: The primary goal of upper gastrointestinal (GI) endoscopic examination is to detect neoplastic lesions in the pharynx, esophagus, and stomach. However, early-stage lesions may frequently be overlooked by conventional white light endoscopy. Since the recent launch of image-enhanced endoscopy, many studies have evaluated its efficacy in diagnosing upper GI neoplasms as well. Linked color imaging (LCI )emphasizes the difference in color to make it easier to detect neoplastic lesions. The aim of this trial is to compare the performance of LCI with white light imaging in detecting upper GI tract neoplastic lesions. 
Author Interviews, Gastrointestinal Disease, Nutrition / 30.09.2020

MedicalResearch.com Interview with: David C. Montrose, Ph.D. Assistant Professor Department of Pathology Renaissance School of Medicine Stony Brook Cancer Center Stony Brook University MedicalResearch.com: What is the background for this study? What are the main findings? Response: Rates of inflammatory bowel disease (IBD) have been increasing worldwide. In parallel with this, fructose consumption has increased. This study demonstrates that feeding high levels of fructose worsens intestinal inflammation in mouse models of inflammatory bowel disease (IBD). This fructose-induced worsening of disease is mediated through effects on gut bacteria.
Author Interviews, COVID -19 Coronavirus, Gastrointestinal Disease / 27.08.2020

MedicalResearch.com Interview with: [caption id="attachment_55240" align="alignleft" width="179"]Dr. Arvind J. Trindade, MD Director of Endoscopy Long Island Jewish Medical Center Division of Gastroenterology, Zucker School of Medicine Hofstra/Northwell, Northwell Health System New Hyde Park, NY Dr. Trindade[/caption] Dr. Arvind J. Trindade, MD Director of Endoscopy Long Island Jewish Medical Center Associate professor at Feinstein Institutes for Medical Research Division of Gastroenterology, Zucker School of Medicine Hofstra/Northwell, Northwell Health System New Hyde Park, NY MedicalResearch.com: What is the background for this study? Response: Although most patients with COVID-19 present with respiratory symptoms, gastrointestinal (GI) symptoms have also been reported in up to 25% of patients. Some case reports have shown acute pancreatitis as the initial presentation in patients with COVID-19, however the literature supporting this is limited. Our study aimed to report the point prevalence, risk factors, and outcomes of hospitalized patients with COVID-19 presenting with acute pancreatitis in a large health system and to compare outcomes of pancreatitis in patients without COVID-19.
Author Interviews, Brigham & Women's - Harvard, Gastrointestinal Disease, Technology / 27.08.2020

MedicalResearch.com Interview with: [caption id="attachment_29758" align="alignleft" width="143"]C. Giovanni Traverso, MB, BChir, PhD Gastroenterologist and biomedical engineer Division of Gastroenterology at BWH Instructor of medicine at Harvard Medical School. Dr. Traverso[/caption] Giovanni Traverso, MB, BChir, PhD Gastroenterologist and biomedical engineer Division of Gastroenterology at BWH Instructor of medicine at Harvard Medical School MedicalResearch.com: What is the background for this study? Response: We began working on this project with the goal to develop liquid drug formulations that could offer an easier-to-swallow alternative to capsules, especially for children. We started to think about whether we could develop liquid formulations that could form a synthetic epithelial lining that could then be used for drug delivery, making it easier for the patient to receive the medication by providing drugs in extended release formats. We discovered that an enzyme called catalase could help assemble molecules of dopamine into the polymer (poly-dopamine). These polymers have muco-adhesion properties, which means that after polymerization, the polymer can attach to the tissue very strongly. Also, catalase is found throughout the digestive tract, with especially high levels in the upper region of the small intestine. This is the first example, to the best of our knowledge, of small intestinal targeting system enabled through in-situ tissue-enzyme-catalyzed polymerization. The coating lasts up to 24 hours, after which it is shed and excreted based on experiments we conducted in pigs.
Author Interviews, Brigham & Women's - Harvard, Cancer Research, Dental Research, Esophageal, Gastrointestinal Disease / 24.07.2020

MedicalResearch.com Interview with: [caption id="attachment_54924" align="alignleft" width="200"]Mingyang Song, MD, ScD. Division of Gastroenterology Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School Department of Nutrition and Department of Epidemiology Harvard T.H. Chan School of Public Health Boston, Massachusetts Dr. Song[/caption] Mingyang Song, MD, ScD. Division of Gastroenterology Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School Department of Nutrition and Department of Epidemiology Harvard T.H. Chan School of Public Health Boston, Massachusetts MedicalResearch.com: What is the background for this study? Response: Recent studies showed a presence of dysbiotic oral microbiome in patients with esophageal and gastric cancer, suggesting a link between oral health and these cancers. However, how periodontal disease and tooth loss may influence the risk of these cancers has been inconsistent.  MedicalResearch.com: What are the main findings? Response: Our findings support a possible role of oral health in the development of upper GI cancer. Individuals with periodontal disease and tooth loss are at higher risk of developing esophageal and gastric adenocarcinoma. The risk is particularly high for individuals with both periodontal disease and tooth loss. 
Author Interviews, Colon Cancer, Gastrointestinal Disease, Infections / 08.05.2020

MedicalResearch.com Interview with: [caption id="attachment_53932" align="alignleft" width="200"]Ulrik Stenz Justesen, MD, DMSc Senior consultant at Department of Clinical Microbiology Odense University Hospital Denmark Dr. Stenz Justesen[/caption] Ulrik Stenz Justesen, MD, DMSc Senior consultant at Department of Clinical Microbiology Odense University Hospital Denmark  MedicalResearch.com: What is the background for this study? Response: Anaerobic bacteria are bacteria that do not require oxygen for energy production, and live in various environments including the human gut, where they usually do not cause infections directly. Previous studies have reported an association between bacteria from the Bovis group streptococci, Clostridium septicum and colorectal cancer (CRC). Recently associations between different Bacteroides species., Fusobacterium nucleatum and CRC have also been reported. We aimed to investigate this further in a large-scale study. 
Author Interviews, Gastrointestinal Disease / 06.05.2020

MedicalResearch.com Interview with: [caption id="attachment_54111" align="alignleft" width="140"]Gregory S. Sayuk, MD, MPH John T. Milliken Department of Medicine Division of Gastroenterology Associate Professor of Medicine and Psychiatry Associate Director, Fellowship Training Program Washington University School of Medicine Dr. Sayuk[/caption] Gregory S. Sayuk, MD, MPH John T. Milliken Department of Medicine Division of Gastroenterology Associate Professor of Medicine and Psychiatry Associate Director, Fellowship Training Program Washington University School of Medicine MedicalResearch.com: What is the background for this study? Response: The primary objective of this analysis, “Plecanatide for Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome‒Constipation: Analysis of Abdominal Pain from Four Randomized Phase 3 Clinical Trials,” was to determine the impact of plecanatide on abdominal pain in patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), in addition to comparing efficacy results in patient populations with minimal to mild pain versus moderate to severe pain at baseline. This was a post hoc analysis of data from the four large, phase 3 plecanatide pivotal trials in CIC and IBS-C.
Author Interviews, Gastrointestinal Disease, Hepatitis - Liver Disease, Occupational Health, Outcomes & Safety / 30.04.2020

MedicalResearch.com Interview with: [caption id="attachment_54062" align="alignleft" width="195"]Dr-Debashis Reja D. Debashis Reja[/caption] Mishal Reja, MD,  MD Resident in Internal Medicine Robert Wood Johnson University Hospital MedicalResearch.com: What is the background for this study? Response: World Trade Center first responders were exposed to environmental toxicants that have resulted in negative health consequences. Gastrointestinal aerodigestive disorders such as GERD and Barrett’s esophagus have been frequently reported in this population. Additionally, an increasing body of literature has shown that fatty liver disease is not only secondary to metabolic syndrome, diabetes, and obesity, as previously thought, but can also result from environmental and industrial toxicants. Chemicals such as Vinyl Chloride, Tetrachloroethylene, Perchloroethylene, and many others are frequently found in industrial occupations and have resulted in fatty liver disease, steatohepatitis, cirrhosis, and hepatocellular carcinoma. Many of these chemicals were also present at ground zero, thus exposing many of first responders to the hepatotoxic effects of these chemicals. To date this is the first study to look at liver disease in World Trade Center first responders.
Author Interviews, C. difficile, Gastrointestinal Disease, Imperial College, Infections, Transplantation / 30.04.2020

MedicalResearch.com Interview with: [caption id="attachment_54022" align="alignleft" width="149"]Prof. Julian Marchesi Prof. Marchesi[/caption] Prof. Julian Marchesi PhD Professor of Digestive Health Faculty of Medicine, Department of Metabolism, Digestion and Reproduction   [caption id="attachment_54021" align="alignleft" width="149"]Dr.-Benjamin-Mullish Prof. Mullish[/caption] Dr. Benjamin Mullish PhD Faculty of Medicine, Department of Metabolism, Digestion and Reproduction NIHR Clinical Lecturer Imperial College London       MedicalResearch.com: What is the background for this study? Response: Many patients are colonized with bacteria that are resistant to nearly all the antibiotics that we currently have. This antibiotic resistance is a huge public health problem, not least because it may lead to the scenario where a bacterial species moves from the gut and into the bloodstream, causes an infection, and cannot be treated. Such scenarios particularly occur in patients who are particularly prone to getting multiple and frequent courses of antibiotics; this may include patients with particular kidney conditions (who may be vulnerable to recurrent urinary tract infections (UTIs)), and patients with blood cancers (such as leukaemia, who have weak immune systems and are therefore prone to infections). Furthermore, in both sets of patients, to help treat their disease, they may be offered transplants, either a new kidney or new bone marrow. When this transplant happens, the clinician needs to ‘switch off’ their immune system to allow the transplant to work. When the immune system is dialled down, it can no longer stop any invading bacteria, increasing the chance of antibiotic resistance bacteria causing infections, which frequently leads to patient death. 
Author Interviews, Colon Cancer, Gastrointestinal Disease, Pancreatic / 17.04.2020

MedicalResearch.com Interview with: Dr Cristina Bosetti PhD Head of the Unit of Cancer Epidemiology Mario Negri Department of Oncology Milan Italy MedicalResearch.com: What is the background for this study? Response: Aspirin has been known since long time to have a beneficial effect in the primary and secondary prevention of cardiovascular diseases. Additional evidence indicates that it has also a favorable role on the risk of various cancers.
Author Interviews, Biomarkers, Gastrointestinal Disease / 28.03.2020

MedicalResearch.com Interview with: [caption id="attachment_53680" align="alignleft" width="200"]Jean-Frederic Colombel MD The Henry D Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sina New York, NY 10029, USA Dr. Colombel[/caption] Jean-Frederic Colombel MD The Henry D Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sina New York, NY 10029, USA MedicalResearch.com: What is the background for this study? Response: The goals of therapy in Crohn’s disease have shifted from mere control of symptoms also called clinical remission towards combination of clinical and endoscopic remission also called deep remission which is now considered as the new therapeutic “target”. However it has yet to be proven that targeting deep remission instead of clinical remission is able to stop the progression of Crohn’s disease towards bowel damage, complications and hospitalizations. This study is a post-hoc analysis of the CALM trial that was published in The Lancet in 2018 where newly diagnosed patients were randomized to escalate therapy based on symptoms only (control arm) or based on a combination of symptoms and two biomarkers namely C-reactive protein in blood and calprotectin in stools (tight control arm).
Author Interviews, Gastrointestinal Disease, JAMA, Orthopedics, Pediatrics / 17.03.2020

[caption id="attachment_53500" align="alignleft" width="150"]Yun-Han Wang PhD Student Karolinska Institute Yun-Han Wang[/caption] MedicalResearch.com Interview with: Yun-Han Wang, PhD Student Karolinska Institute MedicalResearch.com: What is the background for this study? Response: Proton pump inhibitor (PPI) use has been linked to increased risk of fracture in adults. Despite an increasing trend in prescription of PPIs in children, there is scarce evidence regarding this safety concern in pediatric patients.